BILLERICA, Mass., Jan. 19, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced that is has donated $10,000 each to the American Diabetes Association (ADA) and the Juvenile Diabetes Research Foundation (JDRF). Insulet employees raised the funds for these charitable donations during November's National Diabetes Awareness Month as part of a company-sponsored three-day initiative in which thousands of clinicians across the U.S. wore a demo of the OmniPod System. Insulet made a donation to either the ADA or JDRF for each clinician who participated in the program.
"Our mission is to improve the lives of individuals living with diabetes," said Patrick Sullivan, President and Chief Executive Officer. "The successful fundraising efforts by the employees of Insulet underscore their creativity, dedication and commitment to this very important cause. We are grateful for the participation of clinicians across the U.S. in support of our fundraising campaign. We are proud to donate to the ADA and JDRF and look forward to continuing to work closely with these organizations."
Shacey Petrovic, Insulet's Chief Commercial Officer, presented checks to representatives from the ADA and JDRF this week at a recent Insulet event.
"We are grateful for this generous donation from Insulet and its employees, which will help advance our cutting-edge research efforts aimed to prevent, cure and manage all types of diabetes," said Jonathan Webb, Vice President, Corporate Alliances and Grants, American Diabetes Association. "Thanks to decades of critical research made possible through generous supporters like Insulet, people with diabetes are living longer, healthier and more comfortable lives. But as we celebrate advances, we also promise to never let down our guard in both the fight against diabetes and the fight for all people affected by diabetes."
"JDRF works tirelessly to find life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications," said Margo K. Lucero, Senior Vice President, Corporate and International Development of JDRF. "We graciously accept this donation from Insulet and its employees who share our desire to not only research for tomorrow, but find the best possible diabetes treatments for today."
About the OmniPod Insulin Management System:
OmniPod is a unique and discreet insulin delivery system designed to provide people living with diabetes the freedom, simplicity and control that conventional "tubed" insulin pumps and multiple daily injections cannot provide. The OmniPod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user's personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. Our small, light-weight Pod can be worn almost anywhere on the body and, because it is waterproof, there is no need to remove when showering, swimming or performing other activities. This means that OmniPod can provide up to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The OmniPod's cannula insertion is quick, simple, and virtually pain-free. The user simply pushes a button on the PDM and the Pod's cannula automatically inserts, reducing complications and the chance for human error.
The OmniPod System is the world's first commercially available tube-free insulin delivery system that allows patients to live untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump therapy, the OmniPod System offers freedom for our users to live life on their own terms and with the ease of use they deserve.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor of diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit the Company's blog: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.
JDRF is a global organization funding type 1 diabetes research. JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since its inception and collaborates with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with type 1 diabetes. JDRF's staff and volunteers are in more than 100 locations throughout the United States with six international affiliates. For more information, please visit http://jdrf.org/.
ADA funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, ADA's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please visit http://www.diabetes.org/.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 26, 2015 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations and Media Contact:
Deborah R. Gordon Vice President, Investor Relations and Corporate Communications (978) 600-7717 email@example.com
SOURCE Insulet Corporation